Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer
Tiseo, M.; Ardizzoni, A.; Cafferata, M.Argenide.; Loprevite, M.; Chiaramondia, M.; Filiberti, R.; Marroni, P.; Grossi, F.; Paganuzzi, M.
Anticancer Research 28(1b): 507-513
2008
ISSN/ISBN: 0250-7005 PMID: 18383893 Document Number: 620378
Background: The Predictive and prognostic role of neuron-specific enolase (NSE) in non-small cell lung cancer (NSCLC) is still under debate. Patients and Methods: To study these aspects, serum NSE was prospectively measured at baseline of first-line chemotherapy treatment and tested for correlation with clinical outcome in 129 advanced NSCLC patients. Results: An objective response was achieved in 2 7 out of 65 (41.5%) patients with NSE <8.6 ng/ml and in 38 out of 64 (59.4%) patients with NSE >= 8.6 ng/ml (p = 0.05). Logistic analysis confirmed the positive association between objective response and NSE values >= 8.6 ng/ml (odds ratio=1.69; 95% confidence interval: 1.09-2.63; p=0.02). Overall median survival was 10.8 months. A statistically significant prognostic effect on survival was found for performance status, stage and response to treatment, but not for baseline NSE value. Conclusion: Based on these data, baseline circulating tumor NSE levels appear to have a weak predictive role, but not a prognostic significance in patients with advanced NSCLC submitted to standard chemotherapy.